Viridian Therapeutics, Inc. announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors. Dr. Gheuens is the Chief Medical Officer (CMO) and Head of R&D of Agios Pharmaceuticals, Inc. Dr. Gheuens joined Agios in 2019, was promoted to CMO in 2021, and assumed leadership of the R&D organization in 2022. During her time at Agios, she has overseen early- and late-stage clinical development globallyacross multiple indications, including pyruvate kinase deficiency, thalassemia, and sickle cell disease.

Prior to Agios, Dr. Gheuens held roles of increasing responsibility at Biogen in the areas of safety, medical affairs, and clinical development. Before transitioning to industry, she was a clinician at Boston?s Beth Israel Deaconess Medical Center (BIDMC), taking care of patients with HIV and neurological complications while also researching progressive multifocal leukoencephalopathy. Dr. Gheuens received her medical degree from the Free University of Brussels (VUB), Belgium, and completed her neurology residency at the University Hospital of the Free University of Brussels, Belgium, followed by an HIV/neurology fellowship at BIDMC.

She also holds a Ph.D. in Medical Sciences from the University of Antwerp, Belgium, and a Master?s in Medical Sciences from Harvard Medical School.